bacteriophage

JPWO2023210732A5Pending Publication Date: 2026-06-12
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Filing Date
2023-04-27
Publication Date
2026-06-12

AI Technical Summary

⚠Technical Problem

Current treatments for non-tuberculous mycobacterial diseases, such as pulmonary MAC disease, often rely on multidrug therapy with macrolide antibiotics, but there is a need for more effective alternatives due to the limitations of existing antibiotic therapies.

⚗Method used

Development of bacteriophages with lytic activity against Mycobacterium avium and Mycobacterium intracellulare, specifically bacteriophages lacking integrase and immunity repressor genes, which are used to create pharmaceutical compositions for preventing or treating non-tuberculous mycobacterial diseases.

🎯Benefits of technology

The bacteriophages exhibit excellent bactericidal activity against Mycobacterium avium and Mycobacterium intracellulare, providing a promising treatment option for non-tuberculous mycobacterial diseases, particularly pulmonary MAC disease, with sustained activity over time and efficacy in both in vitro and in vivo models.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention addresses the problem of providing a bacteriophage having bacteriolysis activity against Mycobacterium avium and / or Mycobacterium intracellulare. The present invention provides a bacteriophage having bacteriolysis activity against Mycobacterium avium and / or Mycobacterium intracellulare, the genome of said bacteriophage containing a nucleic acid sequence shown in the genome of a bacteriophage identified by one of deposition numbers NITE BP-03513 to 03521.
Need to check novelty before this filing date? Find Prior Art